Michael M. Wick

Michael M. Wick, MD, PhD, Chairman and Chief Executive Officer, joined
Telik, Inc. in December 1997 as Executive Vice President, Research and
Development and a Director. From 1995 to 1997, he was Senior Vice
President of Research for CV Therapeutics. Dr. Wick served as Executive
Director of oncology/immunology drug discovery and clinical research at
Lederle Laboratories, a division of American Cyanamid, from 1990 to
1995, and also directed the Cyanamid/Immunex joint oncology research
program. He began his career at Harvard Medical School, where he served
as an Associate Professor from 1981 to 1994 and Chief of the Melanoma
Clinic and Laboratory of Molecular Dermatologic Oncology at the Dana
Farber Cancer Institute from 1980 to 1992. Dr. Wick holds a PhD degree
in Chemistry from Harvard University and an MD degree from Harvard
Medical School.